Barrington Research Upgrades Conceptus (CPTS) to Outperform
More News related to CPTS
- Conceptus(R) to Present at the Piper Jaffray 21st Annual Healthcare Conference
- Conceptus(R) to Continue Patent Infringement Suit against Adiana(R) Permanent Contraception System
- SunTrust Downgrades Conceptus (CPTS) to Neutral
- Conceptus(R) to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Essure(R) to Be Highlighted at 18th Annual Congress of the European Society for Gynaecological Endoscopy
More News related to Upgrades
- Hydrogenics Resumes Trading Under NASDAQ Symbol "HYGS"
- Varian Medical (VAR) to Highlight its New Range of Detectors at Annual RSNA Meeting in Chicago
- Manulife (MFC) Confirms No Exposure to Dubai World
- Activision's (ATVI) Call of Duty Amasses $3 Billion in Global Sales
- Seiko Epson to Transfer Sales Function of Small and Medium-Sized TFT LCD Business to Sony (SNE)
Barrington Research upgrades Conceptus (Nasdaq: CPTS) to Outperform. Price target $23.
To see more analyst ratings on CPTS Click Here.
Conceptus, Inc. designs, develops, and markets minimally invasive devices for reproductive medical applications in the United States.
Related Categories
UpgradesStocks Mentioned
-0.57Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
